DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kkkmcc/uveal_melanoma) has announced the addition of the "Uveal Melanoma - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Array BioPharma Inc.
- AstraZeneca PLC
- Celldex Therapeutics, Inc.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
- Spectrum Pharmaceuticals, Inc.
- Dendritic Cell Therapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma
- glembatumumab vedotin
- pasireotide LAR
- selumetinib sulfate
- sotrastaurin acetate
- sunitinib malate
- trametinib dimethyl sulfoxide + uprosertib
- vincristine sulfate
For more information visit http://www.researchandmarkets.com/research/kkkmcc/uveal_melanoma